From Name:
From Email:
To Name:
To Email:

Optional Message:


Sorafenib slows progression in advanced thyroid cancer

from CancerNetwork

At the 2013 meeting of the American Society of Clinical Oncology, there were promising results for patients with metastatic differentiated thyroid cancer refractory to standard treatment with radioactive iodine. Investigators from the international randomized phase III DECISION trial found treatment with the multitargeted tyrosine kinase inhibitor sorafenib, which inhibits tumor growth signaling and angiogenesis, delayed disease progression by five months in patients with metastatic DTC that had progressed on RAI therapy. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063